The effects of EGFR signalling on cancer glucose metabolism may be driven through the PI3K/AKT/mTORC1 pathway (Jung et al., 2019; Makinoshima et al., 2015), mTORC2 (Masui et al., 2013), the transcription factor c-Myc (Babic et al., 2013; Masui et al., 2013), PKM2 phosphorylation (Lim et al., 2016), or stabilisation of the sodium/glucose cotransporter 1 (SGLT1) (Weihua et al., 2008). This evidence concerns the gene EGFR and cancer.